|
🐜
|
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
29 auth.
R. Levine,
M. Wadleigh,
J. Cools,
B. Ebert,
G. Wernig,
B. Huntly,
T. Boggon,
I. Wlodarska,
Jennifer J. Clark,
Sandra A. Moore,
Jennifer Adelsperger,
Sumin Koo,
Jeffrey C. Lee,
S. Gabriel,
T. Mercher,
...
A. D’Andrea,
S. Fröhling,
K. Döhner,
P. Marynen,
P. Vandenberghe,
R. Mesa,
A. Tefferi,
J. Griffin,
M. Eck,
W. Sellers,
M. Meyerson,
T. Golub,
Stephanie J. Lee,
D. Gilliland
|
11 |
2005 |
11
🐜
|
|
🐜
|
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
17 auth.
Y. Pikman,
Benjamin H. Lee,
T. Mercher,
Elizabeth Mcdowell,
Benjamin L Ebert,
M. Gozo,
A. Cuker,
G. Wernig,
Sandra A. Moore,
I. Galinsky,
...
D. DeAngelo,
Jennifer J. Clark,
Stephanie J Lee,
Todd R. Golub,
M. Wadleigh,
D. G. Gilliland,
Ross L. Levine
|
10 |
2006 |
10
🐜
|
|
🐜
|
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
19 auth.
G. Wernig,
M. Kharas,
R. Okabe,
Sandra A. Moore,
Dena S. Leeman,
Dana E. Cullen,
M. Gozo,
Elizabeth Mcdowell,
Ross L. Levine,
J. Doukas,
...
C. Mak,
G. Noronha,
Michael Martin,
Y. Ko,
Benjamin H. Lee,
R. Soll,
A. Tefferi,
J. Hood,
D. Gilliland
|
8 |
2008 |
8
🐜
|
|
🐜
|
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
25 auth.
D. Walters,
D. Walters,
T. Mercher,
T. Gu,
T. O'hare,
T. O'hare,
J. Tyner,
M. Loriaux,
V. Goss,
Kimberly A. Lee,
C. Eide,
M. Wong,
E. Stoffregen,
Laura S. McGreevey,
J. Nardone,
...
Sandra A. Moore,
J. Crispino,
T. Boggon,
M. Heinrich,
M. Heinrich,
M. Deininger,
R. Polakiewicz,
D. Gilliland,
B. Druker,
B. Druker
|
8 |
2006 |
8
🐜
|
|
🐜
|
Notch signaling specifies megakaryocyte development from hematopoietic stem cells.
9 auth.
T. Mercher,
Melanie Cornejo,
C. Sears,
T. Kindler,
Sandra A. Moore,
I. Maillard,
...
W. Pear,
J. Aster,
D. Gilliland
|
7 |
2008 |
7
🐜
|
|
🐜
|
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
12 auth.
T. Mercher,
G. Wernig,
Sandra A. Moore,
R. Levine,
T. Gu,
S. Fröhling,
...
Dana E. Cullen,
R. Polakiewicz,
O. Bernard,
T. Boggon,
Benjamin H. Lee,
D. Gilliland
|
6 |
2006 |
6
🐜
|
|
🐜
|
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo
14 auth.
E. Stover,
Jing Chen,
Benjamin H. Lee,
J. Cools,
Elizabeth Mcdowell,
Jennifer Adelsperger,
Dana E. Cullen,
Allison Coburn,
Sandra A. Moore,
R. Okabe,
...
D. Fabbro,
P. Manley,
J. Griffin,
D. Gilliland
|
6 |
2005 |
6
🐜
|
|
🐜
|
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.
20 auth.
T. Mercher,
G. Raffel,
Sandra A. Moore,
Melanie Cornejo,
Dominique Baudry-Bluteau,
N. Cagnard,
Jonathan L. Jesneck,
Y. Pikman,
Dana E. Cullen,
I. Williams,
...
K. Akashi,
H. Shigematsu,
J. Bourquin,
M. Giovannini,
W. Vainchenker,
R. Levine,
Benjamin H. Lee,
O. Bernard,
D. Gilliland,
D. Gilliland
|
6 |
2009 |
6
🐜
|
|
🐜
|
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
16 auth.
Jing Chen,
Benjamin H. Lee,
I. Williams,
J. Kutok,
C. Mitsiades,
Nicole Duclos,
Sarah L. Cohen,
Jennifer Adelsperger,
R. Okabe,
Allison Coburn,
...
Sandra A. Moore,
B. Huntly,
D. Fabbro,
K. Anderson,
J. Griffin,
D. Gilliland
|
6 |
2005 |
6
🐜
|
|
🐜
|
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.
14 auth.
Melanie Cornejo,
M. Kharas,
Miriam B. Werneck,
Séverine Le Bras,
Sandra A. Moore,
B. Ball,
M. Beylot‐Barry,
S. Rodig,
Jon C. Aster,
Benjamin H. Lee,
...
H. Cantor,
J. Merlio,
D. Gilliland,
T. Mercher
|
6 |
2009 |
6
🐜
|
|
🐜
|
Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease
10 auth.
I. T. Chan,
J. Kutok,
I. Williams,
Sarah L. Cohen,
Sandra A. Moore,
H. Shigematsu,
...
T. Ley,
K. Akashi,
M. L. Beau,
D. Gilliland
|
5 |
2006 |
5
🐜
|
|
🐜
|
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.
12 auth.
C. Wichmann,
Y. Becker,
L. Chen-Wichmann,
V. Vogel,
A. Vojtková,
J. Herglotz,
...
Sandra A. Moore,
J. Koch,
J. Lausen,
W. Mäntele,
H. Gohlke,
M. Grez
|
5 |
2010 |
5
🐜
|
